Inhibrx Shares Up ~20%; Co Earlier Says INBRX-101 Shows Favorable Safety Profile In Patients With Alpha-1 Antitrypsin Deficiency; Says Study Demonstrates Potential To Achieve Normal Alpha-1 Antitrypsin Levels With Monthly Dosing
- Inhibrx, Inc. (NASDAQ:INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline, today announced interim results from a Phase 1 clinical trial evaluating the safety
